Chikungunya Vaccine Candidates: Current Landscape and Future Prospects
Christin Schmidt, Barbara S Schnierle Paul-Ehrlich-Institut, Department of Virology, Section AIDS and Newly Emerging Pathogens, Langen, GermanyCorrespondence: Barbara S Schnierle, Paul-Ehrlich-Institut, Department of Virology, Section AIDS and newly emerging pathogens, Paul-Ehrlich-Strasse 51.59, La...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2022-10-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/chikungunya-vaccine-candidates-current-landscape-and-future-prospects-peer-reviewed-fulltext-article-DDDT |
| _version_ | 1811344643071148032 |
|---|---|
| author | Schmidt C Schnierle BS |
| author_facet | Schmidt C Schnierle BS |
| author_sort | Schmidt C |
| collection | DOAJ |
| description | Christin Schmidt, Barbara S Schnierle Paul-Ehrlich-Institut, Department of Virology, Section AIDS and Newly Emerging Pathogens, Langen, GermanyCorrespondence: Barbara S Schnierle, Paul-Ehrlich-Institut, Department of Virology, Section AIDS and newly emerging pathogens, Paul-Ehrlich-Strasse 51.59, Langen, 63225, Germany, Tel/Fax +49 6103 77 5504, Email barbara.schnierle@pei.deAbstract: Chikungunya virus (CHIKV) is an alphavirus that has spread globally in the last twenty years. Although mortality is rather low, infection can result in debilitating arthralgia that can persist for years. Unfortunately, no treatments or preventive vaccines are currently licensed against CHIKV infections. However, a large range of promising preclinical and clinical vaccine candidates have been developed during recent years. This review will give an introduction into the biology of CHIKV and the immune responses that are induced by infection, and will summarize CHIKV vaccine development.Keywords: alphavirus, vector vaccines, inactivated virus, nucleic acid vaccines, immune response, arthralgia |
| first_indexed | 2024-04-13T19:51:13Z |
| format | Article |
| id | doaj.art-924690a59a124474ba781325fa6a1913 |
| institution | Directory Open Access Journal |
| issn | 1177-8881 |
| language | English |
| last_indexed | 2024-04-13T19:51:13Z |
| publishDate | 2022-10-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj.art-924690a59a124474ba781325fa6a19132022-12-22T02:32:33ZengDove Medical PressDrug Design, Development and Therapy1177-88812022-10-01Volume 163663367379100Chikungunya Vaccine Candidates: Current Landscape and Future ProspectsSchmidt CSchnierle BSChristin Schmidt, Barbara S Schnierle Paul-Ehrlich-Institut, Department of Virology, Section AIDS and Newly Emerging Pathogens, Langen, GermanyCorrespondence: Barbara S Schnierle, Paul-Ehrlich-Institut, Department of Virology, Section AIDS and newly emerging pathogens, Paul-Ehrlich-Strasse 51.59, Langen, 63225, Germany, Tel/Fax +49 6103 77 5504, Email barbara.schnierle@pei.deAbstract: Chikungunya virus (CHIKV) is an alphavirus that has spread globally in the last twenty years. Although mortality is rather low, infection can result in debilitating arthralgia that can persist for years. Unfortunately, no treatments or preventive vaccines are currently licensed against CHIKV infections. However, a large range of promising preclinical and clinical vaccine candidates have been developed during recent years. This review will give an introduction into the biology of CHIKV and the immune responses that are induced by infection, and will summarize CHIKV vaccine development.Keywords: alphavirus, vector vaccines, inactivated virus, nucleic acid vaccines, immune response, arthralgiahttps://www.dovepress.com/chikungunya-vaccine-candidates-current-landscape-and-future-prospects-peer-reviewed-fulltext-article-DDDTalphavirusvector vaccinesinactivated virusnucleic acid vaccinesimmune responsearthralgia |
| spellingShingle | Schmidt C Schnierle BS Chikungunya Vaccine Candidates: Current Landscape and Future Prospects Drug Design, Development and Therapy alphavirus vector vaccines inactivated virus nucleic acid vaccines immune response arthralgia |
| title | Chikungunya Vaccine Candidates: Current Landscape and Future Prospects |
| title_full | Chikungunya Vaccine Candidates: Current Landscape and Future Prospects |
| title_fullStr | Chikungunya Vaccine Candidates: Current Landscape and Future Prospects |
| title_full_unstemmed | Chikungunya Vaccine Candidates: Current Landscape and Future Prospects |
| title_short | Chikungunya Vaccine Candidates: Current Landscape and Future Prospects |
| title_sort | chikungunya vaccine candidates current landscape and future prospects |
| topic | alphavirus vector vaccines inactivated virus nucleic acid vaccines immune response arthralgia |
| url | https://www.dovepress.com/chikungunya-vaccine-candidates-current-landscape-and-future-prospects-peer-reviewed-fulltext-article-DDDT |
| work_keys_str_mv | AT schmidtc chikungunyavaccinecandidatescurrentlandscapeandfutureprospects AT schnierlebs chikungunyavaccinecandidatescurrentlandscapeandfutureprospects |